Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Famotidine for COVID-19  Kuno et al.  LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? PSM retrospective 9,565 patients in the USA (Mar 2020 - Mar 2021) No significant difference in mortality c19early.org Kuno et al., J. Medical Virology, October 2021 Favors famotidine Favors control

The association between famotidine and in-hospital mortality of patients with COVID-19

Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375
Oct 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
risk of death, no change, OR 1.00, p = 0.97, treatment 1,593, control 7,972, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kuno et al., 11 Oct 2021, retrospective, propensity score matching, USA, peer-reviewed, 4 authors, study period 1 March, 2020 - 30 March, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
The association between famotidine and in‐hospital mortality of patients with COVID‐19
MD Toshiki Kuno, Matsuo So, Mai Takahashi, Natalia N Egorova
Journal of Medical Virology, doi:10.1002/jmv.27375
Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. This retrospective study was conducted by utilizing data of 9565 COVID-19 hospitalized patients. Patients treated with and without famotidine were matched by propensity score using a 1:1 matching scheme. A total of 1593 patients (16.7%) received famotidine. In-hospital mortality was similar in patients treated with and without famotidine in the propensity-matched cohorts (28.3% vs. 28.2%, p = 0.97), which remains similar irrespective of severity or concomitant treatment by steroids. Famotidine treatment was not associated with a lower risk of in-hospital mortality of COVID-19 patients.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests. ETHICS STATEMENT This study was approved by the Institutional Review Boards (#2000495) and conducted in accordance with the principles of the Declaration of Helsinki. The waiver of patients' informed consent was also approved by the institutional review boards. AUTHOR CONTRIBUTIONS Toshiki Kuno, Mai Takahashi, and Natalia N. Egorova had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Toshiki
References
Castells, Butterfield, Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management, J Allergy Clin Immunol Pract
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology
Kuno, Miyamoto, Iwagami, Ishimaru, Takahashi et al., The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids, J Antimicrob Chemother
Kuno, So, Miyamoto, Iwagami, Takahashi et al., The association of COVID-19 antibody with in-hospital outcomes in COVID-19 infected patients, J Med Virol, doi:10.1002/jmv.27260
Kuno, So, Takahashi, Egorova, U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients, J Thromb Thrombolysis
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Front Pharmacol
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Mukherjee, Bhattacharya, Bojkova, Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J Biol Chem
Shoaibi, Fortin, Weinstein, Berlin, Ryan, Comparative effectiveness of famotidine in hospitalized COVID-19 patients, Am J Gastroenterol
So, Kabata, Takahashi, Egorova, Kuno, The association of inhaled corticosteroid before admission and survival of patients with COVID-19, J Aerosol Med Pulm Drug Deliv
Sterne, Murthy, Diaz, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit